15 articles for thisTarget

---

The following articles (labelled with PubMed ID or TBD) are for your review

PMID	Data	Article Title	Organization
26670264	73	Fragment-Based Discovery of 2-Aminoquinazolin-4(3H)-ones As Novel Class Nonpeptidomimetic Inhibitors of the Plasmepsins I, II, and IV.	Latvian Institute of Organic Synthesis
24900843	60	Plasmepsin inhibitory activity and structure-guided optimization of a potent hydroxyethylamine-based antimalarial hit.	Latvian Institute of Organic Synthesis
10669559	180	Protease inhibitors: current status and future prospects.	University of Queensland
19635672	35	alpha-Substituted norstatines as the transition-state mimic in inhibitors of multiple digestive vacuole malaria aspartic proteases.	Uppsala University
19328682	13	Expedient solid-phase synthesis of both symmetric and asymmetric diol libraries targeting aspartic proteases.	National University of Singapore
17149873	20	High antiplasmodial activity of novel plasmepsins I and II inhibitors.	University of Milan
16162010	78	Synthesis of malarial plasmepsin inhibitors and prediction of binding modes by molecular dynamics simulations.	Uppsala University
15974592	68	Design and synthesis of potent inhibitors of plasmepsin I and II: X-ray crystal structure of inhibitor in complex with plasmepsin II.	LinköPing University
31913032	86	Plasmepsin Inhibitors in Antimalarial Drug Discovery: Medicinal Chemistry and Target Validation (2000 to Present).	University of Zambia
30529637	76	Peptidomimetic plasmepsin inhibitors with potent anti-malarial activity and selectivity against cathepsin D.	Latvian Institute of Organic Synthesis
29636223	84	2-Aminoquinazolin-4(3H)-one based plasmepsin inhibitors with improved hydrophilicity and selectivity.	Latvian Institute of Organic Synthesis
15658851	42	Selective estrogen receptor modulators with conformationally restricted side chains. Synthesis and structure-activity relationship of ERalpha-selective tetrahydroisoquinoline ligands.	Novartis Pharmaceuticals
15689158	21	Novel transient receptor potential vanilloid 1 receptor antagonists for the treatment of pain: structure-activity relationships for ureas with quinoline, isoquinoline, quinazoline, phthalazine, quinoxaline, and cinnoline moieties.	Abbott Laboratories
18072720	30	Stereospecific high-affinity TRPV1 antagonists: chiral N-(2-Benzyl-3-pivaloyloxypropyl) 2-[4-(methylsulfonylamino)phenyl]propionamide analogues.	Seoul National University
12639546	30	Identification of a high-affinity phosphopeptide inhibitor of Stat3.	The University of Texas At Houston